Russian and US scientists launch type 2 diabetes drug program

Russian and US researchers have launched a joint project aimed at developing an innovation drug candidate to fight type 2 diabetes.

Russian and US researchers have launched a joint project aimed at developing an innovation drug candidate to fight type 2 diabetes, the website of Russia?s ChemRar biotech research company announced earlier this week. A joint R&D agreement has been signed by ChemRar (located in Khimki just outside Moscow), SatRx (a three-year-old ChemRar subsidiary), the Severny biopharma cluster just outside Moscow led by the Moscow Institute of Physics and Technology (MIPT), ChemRar?s Research Institute for Chemical Diversity, and the University of California in San Diego. The partnership calls for access to specific pharmacological models held by the University of California in San Diego and joint translational research with a goal of perfecting innovation TGR-5 non-systemic receptor agonists developed by scientists at MIPT, SatRx and the Institute for Chemical Diversity in Russia. At the moment, the TGR-5 research program is in its preclinical trial phase...